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ABSTRACT  
Recurrent pregnancy loss (RPL) is a significant clinical problem that may occur before the 20 th week of gestation. There is no general 
consensus on how many consecutive abortions are considered as RPL. The goal of this study is to investigate the correlation between 
recurrent miscarriage (RM) and common polymorphisms in angiotensin-converting enzyme (ACE), plasminogen activator inhibitor 1 
(PAI-1) and Methylenetetrahydrofolate Reductase (MTHFR) genes among women experiencing RM. The literature existing in different 
population was searched and based on these finding we conclude that polymorphism in either one of these genes may increase chances of 
miscarriage. 
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INTRODUCTION 
Miscarriage is the most common complication of pregnancy, 
which affects approximately 15% of all clinically recognized 
pregnancies in the general population. Recurrent miscarriage is 
defined as three or more consecutive pregnancy losses before 
the 20th week of gestation. There is a tendency to include those 
with two or more than two abortions in such category. Recurrent 
spontaneous miscarriages (RM) affect up to 5% of fertile 
couples and, many of them, the causes remain unexplained [1]. 
Pregnancy can lead to folate deficiency, therefore an increased 
intake of folic acid during pregnancy is recommended. Folates 
are involved in a series of reactions involving the transfer of a 
carbon atom, holding important roles in two processes: DNA 
synthesis and DNA methylation. The methylene 
tetrahydrofolate reductase (MTHFR) is the essential enzyme for 
the conversion of 5, 10-methylenetetrahydrofolate (5, 10-
methylene-THF) to 5-methyltetrahydrofolate (5-methyl-THF). 
The mutations in the MTHFR gene are present in individuals 
with hyperhomocysteinemia, representing a risk factor for NTD; 
miscarriages in the first trimester of pregnancy, in literature, at 
the level of the MTHFR gene, two polymorphisms have been 
frequently described: C677T and A1298C. These 
polymorphisms have been associated with the termolabile form 
of the MTHFR gene that causes the accumulation of 
homocysteine in the circulation (hyperhomocysteinemia) and 
decrease in folic acid. MTHFR mutations is common worldwide 
with an estimated 10-25% prevalence among various ethnic 
backgrounds the risk of embryonic and fetal loss is increased if 
the MTHFR gene mutation is combined with additional 
thrombophilic factors [2]. 
PAI-1 gene is a key regulating factor in the fibrinolysis cascade. 
Recently, associations between polymorphisms in the PAI-1 and 
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ACE genes and PAI-1 plasma levels have been established. 
Endothelial PAI-1 expression is modulated by a 4G/5G 
polymorphism in the PAI-1 promotor, 675 bp upstream from the 
site of start of transcription. The expression of PAI-1 is also 
infuenced by angiotensin II plasma levels. Angiotensin II is a 
very potent vasoconstrictor that is generated by the angiotensin 
I converting enzyme (ACE), which is play role in blood pressure 
regulation. ACE expression is associated with a deletion 
(D)/insertion (I) polymorphism in ACE gene’s intron 16. 
Comparable to the PAI-1 4G allele, the ACE D allele leads to an 
increased PAI-1 expression, in the result of reduced 
fibrinolysis[3]. 
The ‘physiological remodeling’ of spiral arteries throughout 
pregnancy is mediated by the reninangiotensin system (RAS), 
which is one of the main factors regulating blood pressure, fluid 
and electrolyte balance[4]. Angiotensin converting enzyme 
(ACE) encoded by the ACE gene, is a key component of the 
Renin Angiotensin system which mediating the conversion of 
angiotensin I to angiotensin II. In vitro and in vivo studies 
indicate that ACE interferes with hemostasis by different 
mechanisms, including an influence on fibrinolysis, platelet 
aggregation and blood clotting[5]. Though the human ACE gene 
contains a number of variable polymorphic regions that can be 
of potential use in genetic analysis of populations,[6] the 
insertion/deletion (I/D) polymorphism in intron 16, has been 
extensively investigated. During pregnancy, marked changes in 
hemostasis take place and ACE D/D genotype has been 
proposed as a new thrombophilic factor influencing pregnancy 
negative events[7]. In addition to the well-known vasomotor 
functions, RAS is also involved in key events of the 
inflammatory process by increasing vascular permeability[8] and 
contributing to the recruitment of inflammatory cells[9]. 
Regarding hemostasis, several reactions are modulated by the 
renin-angiotensin system, and evidence exists for an association 
between the ACE D/D genotype and increased risk of 
thrombotic events[10]. Moreover, ACE by bradykinin 
degradation reduces nitric oxide levels, therefore contributing to 
endothelial dysfunction. 
The purpose of this study is to evaluate whether MTHFR, ACE 
and PAI-1 expression Levels affect the early pregnancies and to 
determine the prevalence of the MTHFR, ACE D and PAI-1 
polymorphisms. 
Material and methods 
An electronic search of the databases was investigated covering 
the period from January 2000 through 2012 using the keywords 
miscarriage, spontaneous abortion, pregnancy loss and 
association of MTHFR, ACE and PAL genes. Further searches 
were then carried out using references cited in the identified 
papers. Searches were not circumscribed by date or by language 
if an English abstract was available. Studies were subsequently 
included in the review if the majority of women in a study 
sample (i.e., at least 51%) experienced an early miscarriage (i.e., 
before the 20th week of gestation). Qualitative studies, as noted, 
were included when helpful in formulating hypotheses. 
Miscarriage definition 
Miscarriage, or spontaneous abortion, is the natural termination 
of a pregnancy before the fetus is considered viable. Roughly 
15%–20% of recognized pregnancies end in miscarriage with 
about three quarters occurring before the 12th week of gestation. 
Although clinicians generally consider pregnancies that 
spontaneously terminate prior to the 14th–16th weeks of 
gestation to be miscarriages. The time frames used in research 
studies have ranged most typically, from up to 20 weeks to 27 
weeks of gestation. Miscarriage rates rise dramatically with age, 
from about 27% for women aged 25–29 to about 40% for 
women aged 40 to about 75% for women aged more than or 
equal to 45[11]. 
MTHFR gene   
Methylenetetrahydrofolate reductase (MTHFR) is involved in 
the synthesis of 5- methylenetetrahydrofolate, which is a 
cofactor in the enzymatic formation of methionine from 
homocysteine. The gene encoding MTHFR has been mapped to 
chromosomal region 1p36.3. Mutations in MTHFR gene are 
associated with hyperhomocysteinemia and increased 
thrombotic tendency. A polymorphism of MTHFR (C677T) 
Int J Clin and Biomed Res. 2015;1(4): 50-55 Page 51 
 
 
Recurrent Pregnancy Loss and Association of MTHFR, PAI -1 and Ace Gene Polymorphisms in Women                             Snehlata Pandey et al. 
leads to an alanine to valine amino acid substitution within the 
predicted catalytic domain of MTHFR [12]. 
Eighteen mutations have been reported so far in the MTHFR 
gene, the most common being C677T and A1298C mis-sense 
mutations which have been reported to induce milder form of 
MTHFR deficiency. C677T transition in exon 4 extensively 
studied in the West, makes the enzyme thermolabile with 
decrease in its enzymatic activity[13] due to dissociation of dimer 
into monomers and loss of FAD-binding capacity[14]. The other 
frequent MTHFR mutation in exon 7, i.e. A1298C transversion, 
is not associated with thermolability of the enzyme with no 
impact on plasma total homocysteine; it has not been elaborated. 
Compound heterozygosity for (677CT/1298AC) will have 
similar clinical impact as C677T homozygosity. An individual 
with a 677TT genotype is always reported to have 1298AA 
genotype and vice versa[15]. 
ACE gene 
Angiotensin converting enzyme (ACE) encoded by the ACE 
gene, is a key component of the Renin Angiotensin system 
mediating the conversion of angiotensin I to angiotensin II. In 
vitro and in vivo studies indicate that ACE interferes with 
hemostasis through different mechanisms, including an 
influence on fibrinolysis, platelet aggregation and blood 
clotting.  Though the human ACE gene contains a number of 
variables polymorphic regions that can be of potential use in 
genetic analysis of populations the insertion/ deletion (I/D) 
polymorphism in intron has been extensively investigated. 
During pregnancy, marked changes in hemostasis take place and 
ACE D/D genotype has been proposed as a new thrombophilic 
factor influencing pregnancy negative events. In addition to the 
well-known vasomotor functions, reninangiotensin system is 
also involved in key events of the inflammatory process by 
increasing vascular permeability and contributing to the 
recruitment of inflammatory cells. Regarding hemostasis, 
several reactions are modulated by the renin-angiotensin 
system, and evidence exists for an association between the ACE 
D/D genotype and increased risk of thrombotic events. 
Moreover, ACE by bradykinin degradation reduces nitric oxide 
levels, therefore contributing to endothelial dysfunction[12]. 
 
PAL-1 gene 
PAI-1 is a key regulating component in the fibrinolysis cascade. 
Recently, associations between polymorphisms in the PAI-1 and 
ACE genes and PAI-1 plasma levels have been established. 
Endothelial PAI-1 expression is modulated by a 4G/5G 
polymorphism in the PAI-1 promotor, 675 bp upstream from the 
start site of transcription. PAI-1 expression is also infuenced by 
angiotensin II plasma levels,that is a very potent 
vasoconstrictor, is generated by the angiotensin Iconverting 
enzyme (ACE), which is well known for its role in blood 
pressure regulation. ACE expression is associated with a 
deletion (D)/insertion (I) polymorphism in intron 16 of the ACE 
gene. Comparable to the PAI-1 4G allele, the ACE D allele leads 
to an increased PAI-1 expression, resulting in reduced 
fibrinolysis[16]. 
These two genetic variations have been related to various 
vascular diseases such as myocardial infarction and deep vein 
thrombosis[17-21] as well as to pregnancy-related disorders such 
as severe pre-eclampsia, pregnancy-induced hypertension, or 
serious pregnancy complications such as growth retardation and 
stillbirth[22-24]. 
 
Figure 1. A scheme of the angotensin/fibrinolysis pathway, 
illustrating the key role of angiotensin I-converting enzyme 
and plasminogen activator inhibitor-1. PAI-1 expression is 
increased by the 4G allele of the PAI-1 gene and by the D-
allele of the ACE gene via angiotensin II. 
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As both polymorphisms influence PAI-1 plasma levels and 
thereby plasmin and fibrin concentrations (Figure 1). This 
revealed a significant difference in the prevalence of the 
hypofibrinolytic combination of the PAI-1 4G/4G and ACE D/D 
genotypes, which was present in 13.6% of the RM patients, but 
only in 4.7% of the controls (P = 0.01). In contrast, individuals 
carrying the 4G/5G-D/I genotype (17.4% of the patients versus 
28.3% of the controls; P = 0.02) appeared to have a lower risk 
of RM. The Cochran-Armitage trend test confirmed the 
relationship between a combination of the PAI 4G/4G and ACE 
D/D genotypes and RM (P = 0.02). Logistic regression analysis 
also demonstrated a significant influence of these two factors 
combined (P = 0.03), while the MTHFR C677T genotype were 
not significant variables. By stepwise logistic regression, the 
combination of the PAI-1 4G/4G and ACE D/D genotype was a 
significant positive explanatory variable for miscarriages (P = 
0.01) and a significant independent risk factor for miscarriages 
with an odds ratio of 3.2[25]. 
DISCUSSION 
The relationships between three genetic polymorphisms and 
RPL were surveyed in this study. MTHFR is one of the most 
frequently studied thrombophilic genes controversially 
suspected to be associated with RPL. 
The study by jeddi-tehrani et al. showed that the MTHFR 677C 
⁄ T, and 1298A ⁄C polymorphisms were found to be positively 
associated with RPL in Iranian women. Homozygosity but not 
heterozygosity for PAI-1)675 4G⁄5G polymorphism was 
significantly higher in patients with RPL than in the control 
group. The presence of these both mutations of MTHFR genes 
highly increased the risk of RPL. The data highlights the 
importance of thrombophilia screening in patients with RPL[26]. 
The results of the study by Daniela Neagos et al. showed that 
women with spontaneous abortion have a higher proportion of 
the 677TT genotype compared with the control group and the 
distribution of allelic and genotypic frequencies for 
polymorphism A1298C, does not present significant differences 
between the study group and control. The study also found that 
the frequency of the combined 677TT/1298 AA genotypes is 
higher in the study group compared with in women from 
Romania[27]. 
In another study homozygosity for the D allele of the ACE gene, 
which results in elevated PAI-1 concentrations and 
hypofibrinolysis, is associated with an elevated risk of RM and 
the combination of the D/D genotype with two 4G alleles of the 
PAI-1 promoter, which further increases PAI-1 plasma levels, is 
significantly more frequent in RM patients compared with 
controls demonstrated by[25]. 
V. Vettriselvi et al. study showed No statistically significant 
difference was observed in the distribution of genotypes 
between cases and controls for ACE and MTHFR 
polymorphisms in south Indian women further, the combination 
of MTHFR and ACE genotypes failed to reveal an 
association[12]. 
The Prevalence of methylene tetrahydrofolate reductase 
(MTHFR) gene mutations in South Indian population was 
investigated from a total of 608 samples, 420 adults and 188 
newborns. Detection of mutation was carried out focussing on 
the two most common mutations of the MTHFR gene (C677T 
and A1298C) using PCRbased RFLP method. T-allele 
frequency was almost similar between the newborns and adults 
(0.0904, 0.1012). However, a higher T-allele frequency was 
observed in females (0.1538 and 0.12 in adults and newborns 
respectively) than males (0.0556 and 0.05 in adults and 
newborns respectively) by A. Radha Rama Devi et al. 
Biochemical correlation of fasting plasma total homocysteine to 
MTHFR genotype revealed mild to moderate 
hyperhomocysteinemia in mutants. Plasma total homocysteine 
in males was found to be higher than in females in both normal 
and mutant individuals. TT homozygous women had higher 
plasma homocysteine. The high T-allele frequency, elevated 
plasma homocysteine and low folate intake in women could well 
be a risk factor for birth defects. The gender bias observed in 
this autosomal recessive trait was an interesting finding and is 
discussed[28]. 
The findings of   Ajit K Saxena et al. study reveal that the highest 
(26.7%) incidence was observed in heterozygote (CT) cases 
when compared with controls (24.0%). The individual alleles 
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(T) frequency (0.13%) was also calculated by Hardy Weinberg 
equilibrium showing lack of significant differences (p<0.05). 
Biochemical analysis showed slight variation between 
homocysteine (17.02±14.64 μmol/l) and folates (16.76±8.48 
ng/ml). Cytogenetic study showed chromosomal association 
between D and G – groups, while karyotype of one case is 
mosaic and was also observed. However, the calculated O.R. 
(1.15) suggests that “risk factor” increased to confirm that 
genotypic variants of MTHFR C677T gene polymorphism are 
responsible for fetal viability[29]. 
The study done by Hui chen et al.2014 found a significant 
association between the PAI-1-675G/A polymorphism and the 
risk of RPL under the recessive model (OR = 1.70, 95% CI = 
1.21–2.38). However, no significant association between the 
PAI-1-844G/A polymorphism and RPL was noted. PAI-1-
675G/A (4G/5G) polymorphisms play a potential role in RPL[30]. 
The result of a study by Unfried et al.2002 shows MTHFR allele 
frequencies in women with  recurrent miscarriage and controls 
were 34.6% and 21.6%, respectively, for the T allele (mutant) 
and 65.4% and 78.4%, respectively, for the C allele (wild type) 
(P = .007, odds ratio 1.9, 95% confidence interval 1.2, 3.1). The 
MTHFR genotype frequencies in women with idiopathic 
recurrent miscarriage and controls were: 17.3% (T/T), 34.6% 
(C/T), 48.1% (C/C) and 5.4% (T/T), 32.4% (C/T), 62.2% (C/C), 
respectively (P = .03, odds ratio 3.7, 95% confidence interval 
1.2, 11.8 [T/T versus C/T and C/C]). Serum concentrations of 
homocysteine were significantly higher in carriers of a MTHFR 
mutant allele compared with women with no mutant[31]. 
In the ACE polymorphism D/D genotype was less prevalent in 
RM patients (49%) than in controls (54%) but the difference was 
not significant (p = 0.479). The patients appeared to have a 1.41 
times higher I/D genotype prevalence than the control subjects 
with a risk factor of 1.14, although there was no significant 
difference (p = 0.244). There was no significant difference in 
frequency between the genotype of the patient and control 
groups (p = 0.469). The results show no significant difference 
between the groups. Unexpectedly, 4G/5G appears to be more 
frequent in the controls[32]. 
In addition, many more studies have reported the association of 
MTHFR, ACE and PAL 1 polymorphism and increased risk for 
RPL. On the other hand, several groups have documented a lack 
of association between this polymorphism and RPL. 
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